comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 15:27:56 - browse：62871

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Europe is fastest

focus

leisure time

WSS

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Nearly two

Russian and Belarusian players banned from a women's tennis tournament in Prague

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Stem cell clinics for heart failure: buyer be wary

The cancer drug shortage isn’t new — and neither are the solutions

What AstraZeneca

Medicare details structure of new drug price negotiation program

'Weather

Supreme Court strikes down use of affirmative action

Humana, CVS hope to turn members into patients at clinics

Alkermes shareholders re

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

focus

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

White House drug shortage group privately met with industry

2 US Navy sailors arrested for allegedly spying for China

Attacks on the drug industry will lead to fewer breakthroughs

5 wounded, 2 critically, in Michigan shopping center shooting

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

knowledge

leisure time

leisure time

hotspot